索格列净对1型糖尿病成人肾功能、白蛋白尿、血压和红细胞压积的影响
该研究为52周汇总分析,纳入inTandem1和inTandem2试验中1575例1型糖尿病成人,随机接受索格列净200mg、400mg或安慰剂联合优化胰岛素治疗。结果显示索格列净可带来肾脏血流动力学变化,包括eGFR、血压、白蛋白尿及血液学指标改变,与2型糖尿病中SGLT2抑制剂表现相似,支持进一步研究其心肾获益。
要点
- 索格列净200mg使52周eGFR较基线变化-2.0 mL/min/1.73m2(P=0.010),400mg为-0.5 mL/min/1.73m2(P=0.52)。
- 索格列净200mg和400mg分别降低收缩压2.9和3.6 mmHg(均P<0.0001),降低舒张压1.4和1.6 mmHg。
- 基线UACR≥30 mg/g者中,索格列净200mg和400mg使UACR分别下降23.7%(P=0.054)和18.3%(P=0.18)。
核心结论
- 索格列净与短期和长期肾脏血流动力学变化相关,类似SGLT2抑制剂在2型糖尿病中的表现。
- 索格列净在1型糖尿病成人中的心肾作用值得进一步研究。
研究设计与样本
- 52周汇总分析,纳入inTandem1和inTandem2试验中1575例1型糖尿病成人。
- 参与者随机接受索格列净200mg、400mg或安慰剂,联合优化胰岛素治疗。
主要发现
- 52周时,索格列净200mg和400mg组安慰剂校正的eGFR最小二乘均值变化分别为-2.0 mL/min/1.73m2(P=0.010)和-0.5 mL/min/1.73m2(P=0.52)。
- 收缩压差异分别为-2.9和-3.6 mmHg(均P<0.0001);舒张压变化分别为-1.4 mmHg(P=0.0033)和-1.6 mmHg(P=0.0008)。
- 基线UACR≥30 mg/g者中,索格列净200mg和400mg组UACR分别下降23.7%(P=0.054)和18.3%(P=0.18)。
- 两种索格列净剂量均观察到血清白蛋白和红细胞压积升高、尿酸降低,持续52周。
临床怎么用
- 在1型糖尿病成人中,索格列净可带来eGFR、血压、白蛋白尿及血液学指标的有利变化,提示潜在肾脏保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In people with type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce cardiovascular risk and progression of diabetic kidney disease. Our aim was to determine whether sotagliflozin (SOTA), a dual SGLT1i and SGLT2i, had favorable effects on clinical biomarkers suggestive of kidney protection in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: In this 52-week pooled analysis, 1,575 adults enrolled in the inTandem1 and inTandem2 trials were randomized to SOTA 200 mg, 400 mg, or placebo in addition to optimized insulin therapy. Changes in cardiorenal biomarkers were assessed. RESULTS: At 52 weeks, in response to SOTA 200 and 400 mg, the placebo-corrected least squares mean change from baseline in estimated glomerular filtration rate was -2.0 mL/min/1.73 m2 (P = 0.010) and -0.5 mL/min/1.73 m2 (P = 0.52), respectively. Systolic blood pressure difference was -2.9 and -3.6 mmHg (P < 0.0001 for both); diastolic blood pressure changed by -1.4 (P = 0.0033) and -1.6 mmHg (P = 0.0008). In participants with baseline urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g, UACR decreased by 23.7% (P = 0.054) and 18.3% (P = 0.18) for SOTA 200 and SOTA 400 mg, respectively, versus placebo. Increases in serum albumin and hematocrit and reductions in uric acid were observed throughout 52 weeks with both SOTA doses. CONCLUSIONS: SOTA was associated with short- and long-term renal hemodynamic changes, which were similar to those seen with SGLT2i in type 2 diabetes. Further investigation around cardiorenal effects of SOTA in people with type 1 diabetes is justified.
引用
- van Raalte DH, Bjornstad P, Persson F, et al. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. Diabetes Care. 2019. PMID: 31371432. doi:10.2337/dc19-0937
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。